Suven Life Sciences Ltd

Suven Life Sciences Ltd

Suven Life Sciences Ltd announced the allotment of 2,71,970 equity shares to eligible employees who exercised their vested options under the SLSL ESOP 2020 Scheme. The shares were issued at an exercise price of Rs. 55 each, leading to a total realization of Rs. 1,49,58,350 for the company. Consequently, the company's paid-up equity share capital increased from 26,37,20,583 shares to 26,39,92,553 shares. This allotment is a routine compliance under SEBI regulations.

Suven Life Sciences Ltd

Suven Life Sciences will participate in the BIO International Convention 2026 in San Diego to showcase its differentiated Central Nervous System (CNS) clinical candidates, including late-stage assets for Alzheimer's agitation, major depressive disorder, and narcolepsy. The company aims to engage with global pharmaceutical and biotechnology firms through 62 pre-scheduled meetings to explore partnering strategies, out-licensing, and co-development initiatives for its pipeline. This move seeks to accelerate the development and commercialization of its innovative treatments.